| |
| |
|
| Insider
Information: |
Foehr Matthew W |
| Relationship: |
President and CEO, Dir... |
| City: |
Palo Alto |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
3,948,737 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$33,186,682 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
3,948,737 |
|
|
| Total
Value |
$33,186,682 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
13
|
4
|
|
Stock
price went up :
|
6
|
0
|
| Stock
price went down : |
7
|
4
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-4.0
|
| Percentage
Gain/Loss : |
 32.7%
|
 -89.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ligand Pharmaceuticals Inc |
LGND |
Former Executive Officer |
2022-11-01 |
162,187 |
2011-04-18 |
0 |
Premium* |
|
|
Viking Therapeutics, Inc. |
VKTX |
Director |
2022-05-02 |
111,250 |
2015-05-04 |
0 |
Premium* |
|
|
Qualigen Therapeutics Inc |
QLGN |
Director |
2020-04-10 |
138,635 |
2015-06-24 |
0 |
Premium* |
|
|
OmniAb, Inc |
OABI |
President and CEO, Dir... |
2024-05-24 |
3,536,665 |
2022-11-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
136 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2016-03-17 |
4 |
S |
$96.70 |
$618,880 |
D/D |
(6,400) |
76,662 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2016-03-17 |
4 |
OE |
$9.97 |
$86,241 |
D/D |
8,650 |
78,912 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2016-08-05 |
4 |
S |
$122.14 |
$1,526,750 |
D/D |
(12,500) |
78,912 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2016-08-05 |
4 |
OE |
$9.97 |
$124,625 |
D/D |
12,500 |
91,412 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2016-08-08 |
4 |
OE |
$9.97 |
$41,126 |
D/D |
4,125 |
83,037 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2017-02-15 |
4 |
D |
$104.28 |
$246,831 |
D/D |
(2,367) |
80,670 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2017-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
12,783 |
90,720 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2017-02-24 |
4 |
D |
$100.38 |
$274,339 |
D/D |
(2,733) |
83,176 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2017-03-02 |
4 |
OE |
$9.97 |
$68,584 |
D/D |
6,879 |
97,599 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2017-03-02 |
4 |
S |
$103.39 |
$711,214 |
D/D |
(6,879) |
90,720 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2017-03-03 |
4 |
OE |
$9.97 |
$19,940 |
D/D |
2,000 |
92,720 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2017-05-12 |
4 |
S |
$112.20 |
$630,650 |
D/D |
(5,621) |
92,720 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2017-05-12 |
4 |
OE |
$9.97 |
$56,041 |
D/D |
5,621 |
98,341 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2017-05-15 |
4 |
OE |
$9.97 |
$21,934 |
D/D |
2,200 |
94,920 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2017-08-09 |
4 |
OE |
$9.97 |
$69,292 |
D/D |
6,950 |
95,770 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2017-08-09 |
4 |
S |
$127.51 |
$777,824 |
D/D |
(6,100) |
94,920 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2017-12-28 |
4 |
D |
$138.66 |
$411,959 |
D/D |
(2,971) |
98,494 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2017-12-28 |
4 |
A |
$0.00 |
$0 |
D/D |
5,695 |
101,465 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2018-02-15 |
4 |
D |
$157.18 |
$575,750 |
D/D |
(3,663) |
94,831 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2018-02-23 |
4 |
S |
$152.98 |
$832,824 |
D/D |
(5,444) |
95,835 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2018-02-23 |
4 |
OE |
$9.97 |
$88,785 |
D/D |
6,448 |
101,279 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2018-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,883 |
99,718 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2018-03-06 |
4 |
D |
$165.87 |
$241,673 |
D/D |
(1,457) |
101,201 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2018-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,940 |
102,658 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2018-05-10 |
4 |
OE |
$9.97 |
$139,026 |
D/D |
9,936 |
102,256 |
0 |
- |
|
136 Records found
|
|
Page 2 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
